NBP

NovaBridge Biosciences

Pharmaceutical Preparations · SIC 2834CIK 1778016Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(46.0M)

EPS (Basic, as reported)

$-0.21

Net Margin FY2025

—

ROE FY2025

-20.0%

Total Equity

$231.0M

Shares Out

265M

Business description

NovaBridge Biosciences — Pharmaceutical Preparations. Figures are as reported in each year's original 20-F (foreign private issuer annual report) via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 4 → 4 +0% CAGR

Fiscal yearFY2019⚑FY2020FY2021FY2022FY2023FY2024FY2025

Revenue423614(32)4——

Cost of revenue——(7)(4)———

Research & development(121)(151)(190)(131)(114)(22)(63)

General & administrative(94)(62)(141)(118)(64)(30)(31)

Total operating expenses———(52)(73)(51)(94)

Operating income———(53)(72)(51)(94)

Interest expense00000——

Interest & investment income4434778

Other income (expense), net(3)6313(18)(5)(5)(2)

Pre-tax income(209)74(366)(363)(206)(50)(88)

Income tax expense—(2)00000

Net income(209)72(366)(364)(206)(22)(46)

EPS — basic($28.90)$0.54($2.09)($1.92)($1.08)($0.12)($0.21)

EPS — diluted($28.90)$0.46($2.09)($1.92)($1.08)($0.12)($0.21)

Shares outstanding — basic (M)7134175190191187220

Shares outstanding — diluted (M)7157175190191187220

⚑ Weighted-average shares changed ×19.14 between FY2019 and FY2020 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.